These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26661410)

  • 21. Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus.
    Abbas G; Haq QMI; Hamaed A; Al-Sibani M; Hussain H
    Curr Pharm Des; 2020; 26(4):501-508. PubMed ID: 32003684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Hodge RJ; Nunez DJ
    Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
    Overton HA; Fyfe MC; Reynet C
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S76-81. PubMed ID: 18037923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of leptin in diabetes: metabolic effects.
    Meek TH; Morton GJ
    Diabetologia; 2016 May; 59(5):928-32. PubMed ID: 26969486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twincretin as a potential therapeutic for the management of type 2 diabetes with obesity.
    Usui R; Yabe D; Seino Y
    J Diabetes Investig; 2019 Jul; 10(4):902-905. PubMed ID: 30637966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GPCRs and Insulin Receptor Signaling in Conversation: Novel Avenues for Drug Discovery.
    Gupta MK; Vasudevan NT
    Curr Top Med Chem; 2019; 19(16):1436-1444. PubMed ID: 31512997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid receptors and islet function: therapeutic implications?
    Kebede MA; Alquier T; Latour MG; Poitout V
    Diabetes Obes Metab; 2009 Nov; 11 Suppl 4(Suppl 4):10-20. PubMed ID: 19817784
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipids and immunoinflammatory pathways of beta cell destruction.
    Imai Y; Dobrian AD; Morris MA; Taylor-Fishwick DA; Nadler JL
    Diabetologia; 2016 Apr; 59(4):673-8. PubMed ID: 26868492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
    Gallwitz B
    MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
    [No Abstract]   [Full Text] [Related]  

  • 34. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
    Green BD; Gault VA; O'harte FP; Flatt PR
    Curr Pharm Des; 2004; 10(29):3651-62. PubMed ID: 15579061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.
    Holz GG; Chepurny OG
    Curr Med Chem; 2003 Nov; 10(22):2471-83. PubMed ID: 14529486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GPR40: a therapeutic target for mediating insulin secretion (review).
    Feng XT; Leng J; Xie Z; Li SL; Zhao W; Tang QL
    Int J Mol Med; 2012 Dec; 30(6):1261-6. PubMed ID: 23023155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigational insulin secretagogues for type 2 diabetes.
    Scheen AJ
    Expert Opin Investig Drugs; 2016; 25(4):405-22. PubMed ID: 26881467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic Targets.
    Insel PA; Wilderman A; Zambon AC; Snead AN; Murray F; Aroonsakool N; McDonald DS; Zhou S; McCann T; Zhang L; Sriram K; Chinn AM; Michkov AV; Lynch RM; Overland AC; Corriden R
    Mol Pharmacol; 2015 Jul; 88(1):181-7. PubMed ID: 25737495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes.
    Burant CF
    Diabetes Care; 2013 Aug; 36 Suppl 2(Suppl 2):S175-9. PubMed ID: 23882043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.